Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Yang

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2024
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid MetabolismElysse C Filipe, Sipiththa Velayuthar, Ashleigh Philp, et al.
Research Square|September 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialWungki Park, Catherine O'Connor, Joanne Chou, et al.
Nature Medicine|March 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trialWungki Park, Catherine A O'Connor, Joanne F Chou, et al.
Science Advances|July 3, 2024
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy responseBrooke A Pereira, Shona Ritchie, Cecilia R Chambers, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2024
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid MetabolismElysse C Filipe, Sipiththa Velayuthar, Ashleigh Philp, et al.
Research Square|September 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialWungki Park, Catherine O'Connor, Joanne Chou, et al.
Nature Medicine|March 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trialWungki Park, Catherine A O'Connor, Joanne F Chou, et al.
Science Advances|July 3, 2024
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy responseBrooke A Pereira, Shona Ritchie, Cecilia R Chambers, et al.
Pageof 7